Kukar Lab Receives Generous Gift From Arkuda Therapeutics To Accelerate His Progranulin Research
The Kukar Lab received a generous gift for their project titled, "Establishing the bioactivity of granulins in a mouse model of progranulin deficiency," from Arkuda Therapeutics, a biotechnology company, to conduct research focused on establishing the bioactivity of granulins in a mouse model of progranulin deficiency. The goal of the project is to complete proof-of-concept in vivo efficiency studies to determine if delivery of a single granulin protein in the Grn-/- mouse brain is sufficient to rescue lysosomal dysfunction caused by progranulin (PGRN) deficiency.
Arkuda Therapeutics is focused on discovering and developing therapies with the potential to bring new hope to those affected by frontotemporal dementia and other neurodegenerative diseases. When asked about Arkuda’s support of Dr. Kukar, Gerhard Koenig, Ph.D., President and CEO of Arkuda said: “The scientific literature points to the important roles granulins play in lysosomal health. Our therapeutic approach enhances both the secretion of progranulin and levels of lysosomal granulins. We are excited to support Dr Kukar’s project to help unravel the role of granulins in vivo.”
Thank you to Arkuda Therapeutics for their generous support of the Kukar Lab!